Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 1

Conditions

Neoplasms 5Multiple Myeloma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Platinum-resistant Ovarian Cancer 1Metastatic Castration-resistant Prostate Cancer 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × afuresertib × Clear all
NCT02177682 2021-08-11

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Novartis

Phase 1 Terminated
9 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT01531894 2019-07-09

Continuation Study of the Oral AKT Inhibitor GSK2110183

Novartis

Phase 2 Completed
11 enrolled 8 charts
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02240212 2017-04-11

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Novartis

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02235740 2016-05-04

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Novartis

Phase 1 Terminated
1 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡